☆ 4.7 Article

Cabozantinib-Loaded PLGA Nanoparticles: A Potential Adjuvant Strategy for Surgically Resected High-Risk Non-Metastatic Renal Cell Carcinoma

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Related references

Note: Only part of the references are listed.
Review Oncology

Prognostic Factors for Localized Clear Cell Renal Cell Carcinoma and Their Application in Adjuvant Therapy

Kalle E. Mattila et al.

Summary: Approximately one fifth of newly diagnosed renal cell carcinoma patients have metastatic disease, and over one third of localized patients will develop distant metastases after surgery. Tumor size, grade, and extension into blood vessels are valid factors for predicting disease recurrence after surgery. Ongoing adjuvant therapy trials may reveal prognostic features for high-risk patients.

CANCERS (2022)

Add to Collection
Review Mathematical & Computational Biology

The Efficacy of Adjuvant Targeted Therapy in Patients with Advanced Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

Wingkeung Yiu et al.

Summary: This study aimed to evaluate the efficacy and adverse effects of adjuvant targeted therapy in advanced or metastatic RCC through a systematic evaluation and meta-analysis. The results showed that adjuvant targeted therapy did not have a benefit for DFS and OS and even increased the incidence of adverse events compared to placebo. These findings provide valuable information for clinical decision-making and future management of advanced RCC.

COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE (2022)

Add to Collection
Review Oncology

Nanomedicine tactics in cancer treatment: Challenge and hope

Mazhar Salim Al-Zoubi et al.

Summary: Defeating cancer is the ultimate goal of oncologists, and nanomedicine has provided a new avenue for cancer treatment. The active targeting drug delivery tactic is currently the most effective and least toxic approach. While a group of nanomedicine drug delivery systems have been FDA approved, other formulas are still in clinical trials.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2022)

Add to Collection
Review Oncology

A Nanoparticle's Journey to the Tumor: Strategies to Overcome First-Pass Metabolism and Their Limitations

Joshua J. Milligan et al.

Summary: Nanomedicine, a new emerging cancer therapeutic approach, packages drugs into nanoparticles to improve drug uptake at the tumor site and prevent uptake by peripheral organs, enabling safe delivery of chemotherapeutics and overcoming the limitations of traditional cancer therapeutics. However, there are still challenges in improving drug uptake at the tumor and preventing premature clearance from the body.

CANCERS (2022)

Add to Collection
Article Oncology

Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline

W. Kimryn Rathmell et al.

Summary: The article provides recommendations for the management of patients with metastatic clear cell renal cell carcinoma (ccRCC), including diagnosis, treatment, and participation in clinical trials.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection
Article Engineering, Biomedical

Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy

Wenjing Xu et al.

Summary: Multi-target Tyrosine Kinase Inhibitors (MTKIs) have gained significant attention in tumor therapy due to their ability to inhibit tumor cell proliferation. However, their toxicity and drug resistance have limited their clinical application. In recent years, nano pharmaceutical technology has been used to deliver MTKIs through various types of nanocarriers, overcoming drug resistance and improving therapeutic efficiency.

MATERIALS TODAY BIO (2022)

Add to Collection
Review Polymer Science

Approaches to Improve Macromolecule and Nanoparticle Accumulation in the Tumor Microenvironment by the Enhanced Permeability and Retention Effect

Victor Ejigah et al.

Summary: Passive targeting is a major mechanism for delivering nanocarriers and drug-bearing macromolecules to solid tumors. However, the translation of these efforts to clinical use has been poor. Various barriers and factors contribute to this inefficiency, including the characteristics of the carriers and macromolecules, physiological barriers, and the heterogeneity of tumor blood supply. Overcoming these barriers is essential for improving tumor targeting and therapeutic efficacy.

POLYMERS (2022)

Add to Collection
Review Chemistry, Multidisciplinary

Poly lactic-co-glycolic acid-based nanoparticles as delivery systems for enhanced cancer immunotherapy

Lei Gao et al.

Summary: Cancer immunotherapy is a promising strategy that has revolutionized cancer therapy, with a particular emphasis on cancer vaccines and tumor microenvironment modulation.

FRONTIERS IN CHEMISTRY (2022)

Add to Collection
Review Nutrition & Dietetics

Biopolymeric nanoparticles based effective delivery of bioactive compounds toward the sustainable development of anticancerous therapeutics

Neelam Pathak et al.

Summary: Effective cancer therapy is crucial and nanomedicine plays a significant role. Nanotechnology combined with bioactive compounds offers potential in cancer treatment, and biopolymer-based nanoparticle systems provide an environmentally friendly and cost-effective solution. This review summarizes recent research findings on the use of BNPs in cancer therapy, highlighting their advantages.

FRONTIERS IN NUTRITION (2022)

Add to Collection
Review Oncology

Cabozantinib for the treatment of solid tumors: a systematic review

Pablo Maroto et al.

Summary: This study systematically reviewed the efficacy of cabozantinib monotherapy in various solid tumor types, finding positive treatment outcomes in approved indications and other studied tumors, with consistent safety findings.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)

Add to Collection
Review Oncology

Targeting Myeloid-Derived Suppressor Cells for Premetastatic Niche Disruption After Tumor Resection

Fan Tang et al.

Summary: Surgical resection is a common treatment for primary solid tumors, but high rates of cancer recurrence and metastasis post-surgery contribute to cancer-related mortality. MDSCs play a crucial role in the formation of premetastatic niches and become more immunosuppressive after surgery, suggesting surgery enhances their function. Various therapies targeting MDSCs and associated inflammatory signals may improve long-term survival post-resection.

ANNALS OF SURGICAL ONCOLOGY (2021)

Add to Collection
Article Oncology

Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program

Laurence Albiges et al.

Summary: The study reports treatment patterns and outcomes for patients with mRCC who received cabozantinib through the French Early Access Program. Cabozantinib showed effectiveness in unselected, heavily pretreated mRCC patients, with initiation at 60 mg/day associated with improved outcomes.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection
Article Urology & Nephrology

Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial

Robert J. Motzer et al.

Summary: The PROTECT study found no significant difference in overall survival for patients with locally advanced RCC at high risk of relapse after nephrectomy who received adjuvant therapy with pazopanib or placebo, indicating that pazopanib is not recommended as adjuvant therapy following resection of locally advanced RCC.

EUROPEAN UROLOGY (2021)

Add to Collection
Article Urology & Nephrology

Neoadjuvant and adjuvant immunotherapy in renal cell carcinoma

Alberto Martini et al.

Summary: The treatment landscape for renal cell carcinoma is rapidly evolving, with nine studies currently evaluating the role of immunotherapy in the neoadjuvant setting and four studies in the adjuvant setting.

WORLD JOURNAL OF UROLOGY (2021)

Add to Collection
Review Biochemistry & Molecular Biology

Postoperative Natural Killer Cell Dysfunction: The Prime Suspect in the Case of Metastasis Following Curative Cancer Surgery

Marisa Market et al.

Summary: Surgical resection is essential for treating solid tumors, but the physiological stress and immune suppression following surgery can paradoxically promote cancer recurrence and metastasis. NK cells play a critical role in the formation of micrometastases immediately after surgery, highlighting the importance of strategies to prevent or reverse NK cell dysfunction in improving cancer outcomes post-surgery.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection
Article Oncology

Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

Chun Loo Gan et al.

Summary: The study showed that cabozantinib maintains effectiveness in different lines of treatment, with consideration of patients' tolerance to the drug. Dose reductions may have a positive impact on patients' treatment outcomes.

CANCER MEDICINE (2021)

Add to Collection
Review Cell Biology

Neuroimmune Regulation of Surgery-Associated Metastases

Michael R. Shurin et al.

Summary: Surgery can promote cancer metastasis through mechanisms such as the release of neuroendocrine hormones, immunosuppression, neovascularization, and tissue remodeling. The role of neuroimmune regulation in surgery-associated metastasis is not well understood, highlighting the need for further research in this area.

CELLS (2021)

Add to Collection
Review Health Care Sciences & Services

Nanodrug Delivery Systems Modulate Tumor Vessels to Increase the Enhanced Permeability and Retention Effect

Dong Huang et al.

Summary: This review discusses the use of nanomedicine in antitumor therapy, with a focus on enhancing the EPR effect. By analyzing factors such as abnormal angiogenesis and vascular structure, irregular blood flow, and tumor vessel permeability, ways to increase the therapeutic effect of drugs are explored. Nanoparticles such as liposomes, micelles, and polymers play a crucial role in modulating tumor vessels to improve the EPR effect.

JOURNAL OF PERSONALIZED MEDICINE (2021)

Add to Collection
Editorial Material Urology & Nephrology

New Insights into Adjuvant Therapy in Renal Cell Carcinoma: Is the Chapter of VEGF Inhibitors Definitely Closed?

Florent Peyraud et al.

EUROPEAN UROLOGY (2021)

Add to Collection
Review Materials Science, Multidisciplinary

PLGA-based drug delivery system for combined therapy of cancer: research progress

Zhang Ruirui et al.

Summary: PLGA micro/nano particle drug delivery systems have been widely used in cancer treatment in recent years. The unique properties of PLGA allow for the effective loading of molecules and improvement in bioavailability. Research has focused on the use of PLGA-based drug carrier systems in tumor combination therapy.

MATERIALS RESEARCH EXPRESS (2021)

Add to Collection
Review Oncology

Antiangiogenic Therapy in Clear Cell Renal Carcinoma (CCRC): Pharmacological Basis and Clinical Results

Alessandro Comandone et al.

Summary: In recent years, research on the biological mechanisms and treatment of clear cell renal carcinoma has made significant progress. Neo-angiogenesis has been identified as a key player in tumor growth and metastasis, leading to the approval of antiangiogenic drugs with impressive results in treatment outcomes.

CANCERS (2021)

Add to Collection
Review Oncology

Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma

Myung-Chul Kim et al.

Summary: Clear cell renal cell carcinomas have unique immunological features, showing sensitivity to ICI therapy, despite the need for a better understanding of their molecular and cellular characteristics. Investigating the mechanisms that lead to increased T cell infiltration and deciphering the immune landscape are important for improving the response to ICIs in ccRCC patients.

CANCERS (2021)

Add to Collection
Article Oncology

Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib

Fabio Scirocchi et al.

Summary: Cabozantinib is a multitarget tyrosine kinase inhibitor currently used as standard therapy for medullary thyroid cancer, metastatic renal cell carcinoma, and hepatocellular carcinoma. Research suggests that Cabozantinib may exert an immunostimulatory role by inducing immunogenic stress in cancer cells and modulating dendritic cells directly.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection
Article Oncology

Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study

L. Cerbone et al.

Summary: Cabozantinib has a demonstrated relationship between pharmacokinetics and pharmacodynamics, with severe toxicities associated with higher drug exposure and inefficacy associated with lower drug exposure. Plasma drug monitoring of cabozantinib may be useful in optimizing clinical practice.

ESMO OPEN (2021)

Add to Collection
Article Biology

Development of a highly pulmonary metastatic orthotopic renal cell carcinoma murine model

Jee Soo Park et al.

Summary: The study developed a novel murine RCC model for studying pulmonary metastasis. By implanting cells and monitoring metastasis in mice, the model consistently and efficiently recapitulated RCC pulmonary metastasis, allowing for the elucidation of molecular mechanisms and evaluation of therapeutic modalities.

BIOLOGY OPEN (2021)

Add to Collection
Article Oncology

Tyrosine Kinase Inhibitor Cabozantinib Inhibits Murine Renal Cancer by Activating Innate and Adaptive Immunity

Hongyan Liu et al.

Summary: Cabozantinib treatment for renal cell carcinoma can improve clinical outcomes by activating innate immunity mediated by neutrophils and adaptive immunity mediated by T cells. Cabozantinib induces the expression of chemokines in the tumor microenvironment, increasing intratumor infiltration and anti-tumor function of neutrophils and T cells.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection
Review Oncology

Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives

Mathieu Larroquette et al.

Summary: Adjuvant systemic therapies for non-metastatic RCC have shown limited effectiveness, leading researchers to explore immune therapy and other alternative strategies to improve patient outcomes and increase cure rates.

CANCER TREATMENT REVIEWS (2021)

Add to Collection
Article Oncology

High-risk Surgically Resected Renal Cell Carcinoma: Is There a Role for Adjuvant VEGF-TKI Inhibitors?

Giuseppe Fallara et al.

Summary: The debate over the clinical benefits of adjuvant vascular endothelial growth factor-tyrosine kinase inhibitor (VEGF-TKI) therapy after curative intent nephrectomy for renal cell carcinoma continues. While meta-analyses have shown a marginal benefit in terms of disease free survival (DFS), the risk of high-grade adverse events remains a concern.

CURRENT PROBLEMS IN CANCER (2021)

Add to Collection
Article Pharmacology & Pharmacy

An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma

Andrea Marchetti et al.

Summary: Cabozantinib is gaining attention as a cornerstone therapy for metastatic renal cell carcinoma, both as monotherapy and in combination with immune checkpoint inhibitors. Research has explored its role in different types of renal cell carcinoma, pharmacokinetics, pharmacodynamics, and patients' quality of life.

EXPERT OPINION ON PHARMACOTHERAPY (2021)

Add to Collection
Review Oncology

Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence

Matteo Santoni et al.

Summary: Preclinical evidence demonstrates that cabozantinib has antitumor activity against various cancer cells and works synergistically with other anticancer agents, including immune checkpoint inhibitors and hormone receptor or metabolic pathway inhibitors. Further optimization of cabozantinib treatment requires identifying biomarkers of response and resistance, as well as exploring complementary drug targets. Investigation of adaptive resistance mechanisms, such as epithelial to mesenchymal transition and immunomodulation, and identifying novel drug targets based on cancer stem cell metabolomic phenotypes, are promising approaches.

EXPERT REVIEW OF ANTICANCER THERAPY (2021)

Add to Collection
Review Biochemistry & Molecular Biology

Nanotechnology of Tyrosine Kinase Inhibitors in Cancer Therapy: A Perspective

Eleonora Russo et al.

Summary: Nanotechnology plays a crucial role in modern cancer therapy, improving drug penetration into tumor tissues, extending blood circulation times, reducing side effects, and minimizing drug accumulation in healthy tissues. Developing new nanoparticle systems for small molecule tyrosine kinase inhibitors is essential to enhance drug solubility and reduce toxicity, especially for first-line cancer therapies.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection
Review Medicine, Research & Experimental

Progresses in polymeric nanoparticles for delivery of tyrosine kinase inhibitors

Behrouz Foroughi-Nia et al.

Summary: Tyrosine kinase inhibitors induce apoptosis by altering cellular signals, but some chemotherapeutic drugs have limited efficacy and unpredictability. Nanomedicine has emerged as a modern approach for treating multiple cancers, showing potential advantages over traditional treatments.

LIFE SCIENCES (2021)

Add to Collection
Article Medicine, General & Internal

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

T. K. Choueiri et al.

Summary: The study showed that adjuvant pembrolizumab therapy significantly improved disease-free survival compared to placebo among high-risk kidney cancer patients after surgery, with a positive impact on overall survival as well.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection
Review Oncology

Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis

Ekaterina Laukhtina et al.

Summary: Our analysis found that adjuvant TKI therapy in patients with localized and locally advanced RCC significantly improved disease-free survival (DFS) compared to placebo, but did not result in a significant overall survival (OS) benefit. Additionally, TKI therapy was associated with significant toxicity, suggesting that it may not offer a satisfactory risk and/or benefit balance for all patients.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2021)

Add to Collection
Article Pharmacology & Pharmacy

Physiologically Based Pharmacokinetic Modelling of Cabozantinib to Simulate Enterohepatic Recirculation, Drug-Drug Interaction with Rifampin and Liver Impairment

Bettina Gerner et al.

Summary: The study developed a physiologically based pharmacokinetic model to accurately describe the pharmacokinetic behavior of Cabozantinib (CAB) under various conditions. The model successfully predicted plasma concentrations with low bias and good precision, and served as a basis for further simulations in special populations.

PHARMACEUTICS (2021)

Add to Collection
Review Engineering, Biomedical

The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment

Muyue Yang et al.

Summary: The development and metastasis of tumors are closely linked to the tumor microenvironment (TME). Nanoparticles, with their unique physical properties and design, show potential in efficiently penetrating TME and delivering therapeutic agents to specific components. However, the heterogeneity of tumors and individuals may limit the effectiveness of nanoparticle delivery systems in all types of tumors, calling for further understanding of TME changes at different stages of tumor development for the design of more personalized nanoplatforms.

BIOACTIVE MATERIALS (2021)

Add to Collection
Review Health Care Sciences & Services

Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment

Md Abdus Subhan et al.

Summary: The article discusses the importance of nanodrugs in cancer therapy, targeting tumors through the EPR effect and addressing the lack of selectivity in traditional anticancer drugs.

JOURNAL OF PERSONALIZED MEDICINE (2021)

Add to Collection
Article Oncology

Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses

David H. Aggen et al.

Summary: The study suggests that intratumoral immunosuppression mediated by myeloid-derived suppressor cells and tumor-associated macrophages may lead to immune checkpoint inhibitor resistance in solid tumors. Blocking IL1 beta in combination with anti-PD-1 or cabozantinib has shown increased antitumor activity by reducing immunosuppressive myeloid cells and increasing M1-like tumor-associated macrophages.

CLINICAL CANCER RESEARCH (2021)

Add to Collection
Article Oncology

Adjuvant therapy for high-risk renal cell carcinoma after nephrectomy how many trials are positive? Only one or more than one

A. Ravaud

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection
Article Oncology

Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance)

Ronald C. Chen et al.

CANCER (2020)

Add to Collection
Article Urology & Nephrology

Adjuvant Therapy for Localized High-Risk Renal Cell Carcinoma

Erika Wood et al.

UROLOGIC CLINICS OF NORTH AMERICA (2020)

Add to Collection
Article Oncology

Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial

Tim Eisen et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection
Review Biotechnology & Applied Microbiology

Review of Adjuvant Therapies in Renal Cell Carcinoma: Evidence to Date

Eliana M. C. Tacconi et al.

ONCOTARGETS AND THERAPY (2020)

Add to Collection
Article Urology & Nephrology

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update

Borje Ljungberg et al.

EUROPEAN UROLOGY (2019)

Add to Collection
Article Pharmacology & Pharmacy

Development of sorafenib loaded nanoparticles to improve oral bioavailability using a quality by design approach

Sang Yeob Park et al.

INTERNATIONAL JOURNAL OF PHARMACEUTICS (2019)

Add to Collection
Article Oncology

PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN

Abdallah Flaifel et al.

CLINICAL CANCER RESEARCH (2019)

Add to Collection
Review Pharmacology & Pharmacy

Recent Progress in the Development of Poly(lactic-co-glycolic acid)-Based Nanostructures for Cancer Imaging and Therapy

Ki-Taek Kim et al.

PHARMACEUTICS (2019)

Add to Collection
Review Medicine, General & Internal

Adjuvant Therapy in High-Risk Renal Cell Cancer: A Systematic Review and Meta-analysis

Irbaz B. Riaz et al.

MAYO CLINIC PROCEEDINGS (2019)

Add to Collection
Review Biochemistry & Molecular Biology

Surgical stress and cancer progression: the twisted tango

Zhiwei Chen et al.

MOLECULAR CANCER (2019)

Add to Collection
Review Oncology

Adjuvant Tyrosine Kinase Inhibitors in Treatment of Renal Cell Carcinoma: A Meta-Analysis of Available Clinical Trials

Francesco Massari et al.

CLINICAL GENITOURINARY CANCER (2019)

Add to Collection
Review Materials Science, Biomaterials

Employment of enhanced permeability and retention effect (EPR): Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer

Dnyaneshwar Kalyane et al.

MATERIALS SCIENCE AND ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS (2019)

Add to Collection
Review Oncology

Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence

Paulo Bergerot et al.

MOLECULAR CANCER THERAPEUTICS (2019)

Add to Collection
Article Urology & Nephrology

Establishment of a bioluminescent Renca cell line for renal carcinoma research

Jie Ding et al.

INTERNATIONAL UROLOGY AND NEPHROLOGY (2018)

Add to Collection
Article Urology & Nephrology

Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials

Pierre I. Karakiewicz et al.

CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL (2018)

Add to Collection
Article Urology & Nephrology

Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results

Robert J. Motzer et al.

EUROPEAN UROLOGY (2018)

Add to Collection
Article Oncology

Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial

David Cella et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection
Review Oncology

Adjuvant therapy for locally advanced renal cell carcinoma: A meta-analysis and systematic review

Yangyang Bai et al.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2018)

Add to Collection
Article Oncology

Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial

M. Gross-Goupil et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection
Review Pharmacology & Pharmacy

PLGA-Based Nanoparticles in Cancer Treatment

Sima Rezvantalab et al.

FRONTIERS IN PHARMACOLOGY (2018)

Add to Collection
Review Oncology

Adjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Meta-analysis

Mohamad B. Sonbol et al.

EUROPEAN UROLOGY ONCOLOGY (2018)

Add to Collection
Review Oncology

Does the mobilization of circulating tumour cells during cancer therapy cause metastasis?

Olga A. Martin et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2017)

Add to Collection
Article Oncology

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

Toni K. Choueiri et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection
Article Oncology

Mitochondrial ASncmtRNA-1 and ASncmtRNA-2 as potent targets to inhibit tumor growth and metastasis in the RenCa murine renal adenocarcinoma model

Vincenzo Borgna et al.

ONCOTARGET (2017)

Add to Collection
Review Oncology

Surgery for Cancer: A Trigger for Metastases

Samer Tohme et al.

CANCER RESEARCH (2017)

Add to Collection
Article Medicine, General & Internal

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

Naomi B. Haas et al.

LANCET (2016)

Add to Collection
Article Medicine, General & Internal

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy

A. Ravaud et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection
Article Cell Biology

Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib

Christopher Jedeszko et al.

SCIENCE TRANSLATIONAL MEDICINE (2015)

Add to Collection
Article Oncology

Overexpression of microRNA-95-3p suppresses brain metastasis of lung adenocarcinoma through downregulation of cyclin D1

Su Jin Hwang et al.

ONCOTARGET (2015)

Add to Collection
Review Oncology

Surgery, wound healing, and metastasis: Recent insights and clinical implications

Wim Ceelen et al.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)

Add to Collection
Article Multidisciplinary Sciences

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Amanda Tracz et al.

JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2014)

Add to Collection
Article Urology & Nephrology

Late recurrence of renal cell carcinoma >5 years after surgery: clinicopathological characteristics and prognosis

Yong Hyun Park et al.

BJU INTERNATIONAL (2012)

Add to Collection
Article Urology & Nephrology

Clinical Characteristics and Outcomes of Patients With Recurrence 5 Years After Nephrectomy for Localized Renal Cell Carcinoma

Ari Adamy et al.

JOURNAL OF UROLOGY (2011)

Add to Collection
Article Urology & Nephrology

Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system

JS Lam et al.

JOURNAL OF UROLOGY (2005)

Add to Collection
Article Oncology

Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: An International Multicenter Study

JJ Patard et al.

JOURNAL OF CLINICAL ONCOLOGY (2004)

Add to Collection
Article Urology & Nephrology

Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease

NK Janzen et al.

UROLOGIC CLINICS OF NORTH AMERICA (2003)

Add to Collection
Review Engineering, Biomedical

The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices

RA Jain

BIOMATERIALS (2000)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.